Cetuximab Antibody

SKU: orb1297809

Description

Cetuximab

Research Area

Cardiovascular Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	205923-56-4
MW	152 kDa
Purity	98.00%
Target	EGFR

Bioactivity

−

Target IC50	HCT116 cells:358.0 µg/mL\|EGFR:0.147 nM (Kd, Fixed A431 cells)\|EGFR:0.201 nM (Kd)\|GEO-CR cells:27.7 nM\|SW48 cells:262.4 µg/mL
In Vivo	METHODS: To assay antitumor activity in vivo, Cetuximab (1 mg/injection) was administered intraperitoneally to BALB/c (nu/nu) mice harboring HNSCC tumors UT-SCC-2 or UT-SCC-14 on the 10th, 13th, and 16th days after tumor cell injection. RESULTS: Cetuximab treatment reduced tumor growth in HNSCC xenografts and increased local oxygen partial pressure in tumors. METHODS: To study in vivo antitumor activity, Cetuximab (0.25-1 mg/mouse) was administered intraperitoneally to nude mice bearing xenograft tumors every three days for a minimum of five injections. RESULTS: Treatment with Cetuximab alone effectively delayed the growth of GEO and L2987 tumors for at least 10 days. Borderline activity was observed in A549 and WiDr xenografts. However, Cetuximab did not show any significant anti-tumor activity in HT29, HCT116, LOVO, Colo205, LX-1, HCC70 and N87 models. Read more...
In Vitro	METHODS: Human squamous cell carcinoma (SCC) cells SCC-13Y, SCC-38, SCC-1, and SCC-11B were treated with Cetuximab (30 nM) for 8 days, and cell numbers were measured using a hemacytometer. RESULTS: Cetuximab inhibited cell proliferation of SCC cells in a time-dependent manner. Cetuximab inhibited the growth of SCC cell lines in a time-dependent manner, ranging from 20%-75% compared to untreated controls. METHODS: EGFR mutant cells PC-9 and EGFR wild-type cells PC-14, A549 were treated with Cetuximab (10-100 µg/mL) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: EGFR phosphorylation was strongly expressed in PC-9 and continued to be strongly expressed during Cetuximab treatment.In PC-14 and A549 cells, although the increase in EGFR phosphorylation was reduced by the addition of Cetuximab, phosphorylation was not completely inhibited at the highest concentration. Read more...

Storage & Handling

−

Storage	Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

inhibit, Inhibitor, HER1, EGFR, Epidermal growth factor receptor, ErbB-1, C225, C-225, C 225, anti-EGFR, Cetuximab, Cetuximab (anti-EGFR)

Quality Guarantee

Explore bioreagents carefree to elevate your research. All our products are rigorously tested for performance. If a product does not perform as described on its datasheet, our scientific support team will provide expert troubleshooting, a prompt replacement, or a refund. For full details, please see our Terms & Conditions and Buying Guide. Contact us at support@biorbyt.com.

Quick Database Links

Gene Symbol

EGFR

Documents Download

Datasheet

Product Information

Download

MSDS

Safety Data Sheet

Download

Request a Document

Protocol Information

Find More Protocols